Experimental antibody aims to repair brain connections in rare dementia
NCT ID NCT07154485
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This study tests a new drug called NS101 in 15 people with semantic variant primary progressive aphasia (svPPA), a rare type of frontotemporal dementia that affects language and memory. The drug is an antibody designed to help repair connections between brain cells. The main goal is to check safety, but researchers will also look for signs that it might slow the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NS101 (an antibody that may help repair brain cell connections)
- What this could lead to
- If it works, this could point toward a treatment that slows or improves language and thinking problems in people with this rare form of dementia.
- What could go wrong
- This is a very early, small study (15 people) focused mainly on safety. It may not show any benefit, and the drug could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEMENTIA, FRONTOTEMPORAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.